For example, enhanced Treg activity reported with anti-TNF use in RA – of potential concern in the context of a tumour microenvironment – was specifically linked to monoclonal antibody use rather than that of a receptor fusion protein (102), emphasising that the mechanism of action of targeted therapy may be as important as the molecular targets themselves in this setting. Here, TNF is linked to neoplasm.